Highmark Covers Cognoa Autism Diagnostic Tool For Commercial Members

Health insurer Highmark now covers Cognoa’s FDA-approved autism diagnostic tool, Canvas Dx, for commercial Highmark members. This is Cognoa’s first commercial coverage arrangement. The FDA granted Cognoa marketing authorization for Canvas Dx on June 2, 2021.

Canvas Dx uses artificial intelligence (AI) to help physicians quickly and accurately diagnose risk of autism spectrum disorder (ASD) in children ages 18 months to five years based on input from parents or caregivers, video analysts and health care professionals. The device consists of three main components:

A mobile app for caregivers and parents to answer questions about behavior problems and . . .